Module 1 Vaccinations Flashcards
(109 cards)
1
Q
Hepatitis B (ages)
A
Birth, 1-2MO, 6-18MO
2
Q
Hepatitis B - how many doses are given of this vaccine?
A
3
3
Q
Rotavirus - types of “dose” series
A
RV1 Rotarix = 2 dose series (2 and 4 months)
RV5 Rotateq = 3 dose series (2, 4, 6 months)
4
Q
Rotavirus (ages) - 2 dose series
A
2MO, 4MO,
5
Q
Rotavirus (ages) - 3 dose series
A
2MO, 4MO, 6MO
6
Q
Contraindications of rotavirus vaccination
(3)
A
-Severe allergic reaction (anaphylaxis) after previous dose or to vaccine component
-Severe combined immunodeficiency (SCID)
-History of intussusception
7
Q
Contraindications of Hepatitis B
(2)
A
-Severe allergic reaction (anaphylaxis) after a pervious dose or to a vaccine component (including yeast)
-Pregnancy (Heplisav-B and PreHevbrio are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated
8
Q
How many doses of Rotavirus vaccinations are given?
A
3
9
Q
Dtap (ages)
A
2MO, 4MO, 6MO, 15-18MO, 4-6YR
10
Q
How many doses of Dtap are given?
A
5 doses
11
Q
Haemophilus influenzae type b (Hib) (ages & name) - 4 dose series
A
2MO, 4MO, 6MO; booster 12-15MO
ActHIB, Hiberix, Pentacel, or Vaxelis
12
Q
Haemophilus influenzae type b (Hib) (ages & name) - 3 dose series
A
2MO, 4MO; booster 12-15MO
PedvaxHIB
13
Q
Contraindications for Haemophilus influenzae type b (Hib)
(3)
A
-Severe allergic reaction (anaphylaxis) after a previous dose or to a vaccine component
-For Hiberix, ActHib, and PedvaxHIB only: history of severe allergic rxn to dry natural latex
-Age <6 weeks
14
Q
Precautions for Haemophilus influenzae type b (Hib)
(1)
A
Moderate or severe acute illness with or without fever
15
Q
Pneumococcal conjugate (ages, names of vaccine)
A
-2MO, 4MO, 6MO, 12-15MO
-PCV13 & PCV15
16
Q
Contraindications for pneumococcal conjugate (2)
A
-severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
-severe allergic rxn (anaphylaxis) to any diphtheria-toxoid-containing vaccine or its component
17
Q
Precautions for pneumococcal conjugate (PCV) (1)
A
Moderate or severe acute illness with or without fever
18
Q
Inactivated Poliovirus (IPV) (ages & information on final dose)
A
2MO, 4MO, 6-18MO, 4-6YR
*administer final dose on or after age 4 years and at least 6MO after the previous dose
19
Q
IPV number of doses
A
4 or more doses can be administered before age 4 years when a combination vaccine containing IPV is used
-however, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose
20
Q
COVID-19 (ages)
A
2- or 3- primary series and booster
21
Q
COVID-19 vaccine types/names/options
A
-mRNA: Moderna, Bivalent; Pfizer-BioNTech, Bivalent
-Protein subunit vaccine: novavax, Adjuvanted
22
Q
COVID-19 (ages for both Moderna and Pfizer-BioNTech and how many doses per series)
A
-6MO-4 years –> 2 dose series at 0, 4-8 weeks (Moderna) or 3 dose series at 0, 3-8, 11-16 weeks (Pfizer)
-5-11 years –> 2-dose series at 0, 4-8 weeks (Moderna) or 2-dose series at 0, 3-8 weeks (Pfizer)
-12-18 years –> 2-dose series at 0, 4-8 weeks (Moderna) or 2-dose series at 0, 308 weeks (Novavax, Pfizer)
23
Q
Influenza IIV4 and LAIV4 (ages, doses)
A
-minimum age: 6MO (IIV), 2 years (LAIV4), 18 years (recombinant influenza vaccine, RIV4)
-2 doses separated by at least 4 weeks, for children age 6 months-8 years who have received fewer than 2 influenza vaccine doses before July 1, 2022, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2)
-1 dose for children age 6MO-8 years who have received at least 2 influenza vaccines before July 1, 2022
-1 dose for all persons age 9 years or older
24
Q
Measles, mumps, rubella (MMR) (ages, # of doses)
A
*Minimum age is 12 months for routine vaccination
-2 dose series at age 12-15MO, age 4-6YR
-MMR or MMRV may be administered
*For dose 1 in children 12-47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference
25
Varicella (VAR) (ages, # of doses)
*Minimum age: 12MO
-2 dose series at age 12-15MO, 4-6YR
-VAR or MMRV may be administered
-Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4 weeks may be counted as valid
*For dose 1 in children age 12-47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
26
Hepatitis A (HepA) (ages, # of doses)
*Minimum age: 12 months for routine vaccination
-2 doses series (minimum interval: 6 months) at age 12-23 months
27
Tetanus, diphtheria, and acellular pertussis (Tdap) (ages, # of doses)
-*Minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination
-Adolescents age 11-12 years: 1 dose Tdap
-Pregnancy: 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27-36
-Tdap may be administered regardless of the interval since the last tetanus- and Diphtheria-toxoid-containing vaccine
28
Human papillomavirus (HPV) (ages, # of doses)
*Minimum age: 9 years
-HPV vaccination routinely recommended at age 11-12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
-2 or 3-dose series depending on age at initial vaccination
-->age 9-14 years at initial vaccination: 2 dose series at 0, 6-12 months (minimum internal: 5 months; repeat dose if administered too soon)
--> age 15 years or older at initial vaccination: 3 dose series at 0, 1-2 months, 6 months to dose 3: 5 months; repeat dose if administered too soon
*if vaccination schedule interrupted, does not need to be restarted
29
Meningococcal (MenACWY-D: >=9MO, MenACWY-CRM: >=2MO, MenACWY-TT>=2YRs) (ages, # of doses)
-2 dose series at age 11-12 years; 16 years
30
Pneumococcal polysaccharide (PPSV23) (ages, # of doses)
*Minimum age: 6 weeks (PCV13, PCV15) and 2 years PPSV23)
-4 dose series at 2, 4, 6, 12-15MO
31
Dengue (DEN4CYD: 9-16YRs) (age, # of doses)
*Minimum age: 9 years
-age 9-16 years living in areas with endemic dengue AND have laboratory confirmation of previous dengue infection
-3 dose series administered at 0, 6, and 12 months
-Endemic areas: Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau
*Dengue vaccine should not be administered to children traveling to or visiting endemic dengue areas
32
Hepatitis B - Mother is HBsAg-positive
-Birth dose (monovalent HepB vaccine only): administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight
-birth weight <2000g: administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses)
-Final (3rd or 4th) dose: administer at age 6 months (minimum age 24 weeks)
-Test for HBsAg and anti-HBs at age 9-12 months
33
Hepatitis B - Mother is HBsAg-unknown
*manage infant as if mother is HBsAg-positive
-Birth dose: birth weight >=2000g - administer HepB vaccine w/i 12 hours of birth; if mother is determined HBsAg-positive, administer HBIG ASAP (in separate limb), but no later than 7 days of age. Birth weight <2000g - administer HepB vaccine and HBIG (in separate limbs) w/i 12 hours of birth; administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses)
-Final (3rd or 4th) dose: administer at age 6 months (minimum age 24 weeks)
*If mother is determined to be HBsAg-positive or unknown, test for HBsAg and anti-HBs at age 9-12 months. If HepB series is delayed, test 1-2 months after final dose. Do not test before age 9 months.
34
Contraindications for Dengue (DEN4CYD)
(3)
-Severe allergic rxn (anaphylaxis) after previous dose or to a vaccine component
-Severe immunodeficiency (hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised
-Lack of laboratory confirmation of a previous Dengue infection
35
Precautions of Dengue (DEN4CYD)
(3)
-Pregnancy
-HIV infection without evidence of severe immunosuppression
-Moderate or severe acute illness with or without fever
36
Contraindications for DTap and DT
(2)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
-For DTap only: encephalopathy (i.e. coma, dec level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP
37
Precautions for DTaP and DT
(4)
-Guillain-Barre syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid-containing vaccine
-History of Arthus-type hypersensitivity rxns after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine
-For DTaP only: progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized
-Moderate or severe acute illness with or without fever
38
Contraindications for Hepatitis A
(1)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component including neomycin
39
Precautions for Hepatitis A
(1)
-Moderate or severe acute illness with or without fever
40
Precautions for Hepatitis B
(1)
-Moderate or severe acute illness with or without fever
41
Contraindications for Hepatitis A- Hepatitis B vaccine (HepA-HepB, Trinrix)
(1)
Severe allergic rxn (anaphylaxis) after previous dose or two a vaccine component including neomycin and yeast
42
Precautions for Hepatitis A- Hepatitis B vaccine (HepA-HepB, Trinrix)
(1)
-Moderate or severe acute illness with or without fever
43
Contraindications for HPV
(2)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
0Pregnancy: HPV vaccination not recommended
44
Precautions for HPV
(1)
Moderate or severe acute illness with or without fever
45
Contraindications for MMR
(4)
-Severe allergic fxn (anaphylaxis) after a previous dose or to a vaccine component
-Severe immunodeficiency (hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised
-Pregnancy
-Family hx of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
46
Precautions for MMR
(5)
-Recent (<=11 months) receipt of antibody-containing blood products (specific interval depends on product)
-History of thrombocytopenia or thrombocytopenic purpura
-Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing
-Moderate or severe acute illness with or without fever
-For MMRV only: personal or family (sibling or parent,) hx of seizures of any etiology
47
Contraindications of Meningococcal ACWY
(3)
Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
-For MenACWY-D and Men ACWY-CRM only: severe allergic rxn to any diphtheria toxoid- or CRM - containing vaccine
-For MenACWY-TT only: severe allergic rxn to a tetanus toxoid-containing vaccine
48
Precautions for meningococcal ACWY
(3)
-For MenACWY-CRM only: preterm birth if less than age 9 months
-Moderate or severe acute illness with or without fever
49
Contraindications for Meningococcal B (MenB), (Bexsero), (Trumenba)
(1)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
50
Precations for Meningococcal B (MenB), (Bexsero), (Trumenba)
(3)
-Pregnancy
-For MenB-4C only; Latex sensitivity
-Moderate or severe acute illness with or without fever
51
Contraindications for PCV
(2)
-Severe allergic rxn (anapylasis) after a previous dose or to a vaccine component
-Severe allergic rxn (anaphylaxis) to any diphtheria-toxoid-containing vaccine or its component
52
Precautions for PCV
-Moderate or severe acute illness with or without fever
53
Contraindications for pneumococcal polysaccharide (PPSV23)
(1)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
54
Precautions for Pneumocococcal polysaccharide (PPSV23)
(1)
Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
55
Contraindications for poliovirus vaccine (IPV)
(1)
-severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
56
Precautions for poliovirus vaccine (IPV)
(2)
-Pregnancy
-Moderate or severe acute illness with or without fever
57
Precautions for rotavirus
(4)
-Altered immunocompetence other than SCID
-Chronic gastrointestinal disease
-RV1 only: spina bifida or bladder exstrophy
-Moderate or severe acute illness with or without fever
58
Contraindications for Tdap and Td
(2)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
-For Tdap only: Encephalopathy (coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap
59
Precautions for Tdap and Td
(4)
-Guillain-Barre syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing vaccine
-History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine
-For Tdap only: progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized
-Moderate or severe acute illness with or without fever
60
Contraindications for Varicella (VAR)
(4)
-Severe allergic rxn (anaphylaxis) after a previous dose or to a vaccine component
-Severe immunodeficiency (hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised
-Pregnancy
-Family hx of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent
61
Precautions for Varicella (VAR)
(5)
-Recent (<=11months) receipt of antibody-containing blood product (specific interval depends on product)
-Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination
-Use of aspirin or aspirin-containing products
-Moderate or severe acute illness with or without fever
-If using MMRV, see MMR/MMRV for additional precautions
62
COVID-19
-1vCOV-mRNA: Comirnaty/Pfizer-BioNTech COVID-19 Vaccine; SPIKEVAX/Moderna COVID-19 Vaccine
-2vCOV-mRNA: Pfizer-BioNTech COVID-19 Vaccine, Bivalent; Moderna COVID-19 Vaccine, Bivalent
-1vCOV-apS: Novavax COVID-19 Vaccine
-
63
DEN4CYD
-Dengue vaccine
-Dengvaxia
64
DTap
-Diphtheria, tetanus, and acellular pertussis vaccine
-Daptacel; Infanrix
65
DT
-Diphtheria, tetanus vaccine
-No Trade Name
66
Hib (PRP-T)
-Haemophilus influenzae type B vaccine
-ActHIB; Hiberix
67
Hib (PRP-OMP)
-Haemophilus influenza type B vaccine
-PedvaxHIB
68
HepA
-Hepatitis A vaccine
-Havrix; Vaqta
69
HepB
-Hepatitis B vaccine
-Engerix-B; Recombivax HB
70
HPV
-Human papillomavirus vaccine
-Gardasil 9
71
IIV4
-Influenza vaccine (inactivated)
-Multiple
72
LAIV4
-Influenza vaccine (live, attenuated)
-FluMist Quadrivalent
73
MMR
-Measles, mumps, and rubella vaccine
-M-M-R II; Priorix
74
MenACWY-D
-Meningococcal serogroups A, C, W, Y vaccine
-Menactra
75
MenACWY-CRM
-Meningococcal serogroups A, C, W, Y vaccine
-Menveo
76
MenACWY-TT
-Meningococcal serogroups A, C, W, Y vaccine
-MenQuadfi
77
MenB-4C
-Meningococcal serogroup B vaccine
-Bexsero
78
MenB-FHbp
-Meningococcal serogroup B vaccine
-Trumenba
79
PCV13
-Pneumococcal conjugate vaccine
-Prevnar 13
80
PCV15
-Pneumococcal conjugate vaccine
-Vaxneuvance
81
PPSV23
-Pneumococcal polysaccharide vaccine
-Pneumovax 23
82
IPV
-Poliovirus vaccine (inactivated)
-IPOL
83
RV1
RV5
-Rotavirus
-Rotarix; RotaTeq
84
Tdap
-Tetanus, diphtheria, and acellular pertussis vaccine
-Adacel; Boostrix
85
Td
-Tetanus and diphtheria vaccine
-Tenivac; TDvax
86
VAR
-Varicella vaccine
-Varivax
87
Pediarix
-Combination vaccine
-Dtap-HepB-IPV
88
Pentacel
-Combination vaccine
-DTaP-IPV/Hib
89
Kinrix; Quadracel
-Combination vaccine
-DTaP-IPV
90
Vaxelis
-Combination vaccine
-DTaP-IPV-Hib-HepB
91
ProQuad
-Combination vaccine
-MMRV
92
Moderna and children
Children ages six months to five years can receive two doses of Moderna in the primary series, given within 4-8 weeks apart
93
Pfizer-BioNTech and children
Children six months to 4 years old receiving Pfizer will require three doses of the vaccine in the primary series
-both first and second doses should be separated by three to eight weeks, and the second and third doses should be separated by at least eight weeks
-children receiving Pfizer who are over age of five, will require two doses of Pfizer-BioNTech vaccine given eight weeks apart
94
herd immunity
85% of population vaccinated
95
Active immunity
resistance developed in response to infection with an agent resulting in antibody production
-active immunity is usually permanent
-can be either naturally acquired through exposure and infection with the disease or artificially acquired through immunization
-onset is 2-4 weeks and duration is years to lifetime
96
Passive immunity
A person is given antibodies to a disease rather than producing them through his or her own immune system
-this is short term immunity through introduction of antibodies to a disease
-can occur naturally as in the passage of antibodies from the mother to the fetus during pregnancy or artificially acquired through injection of antibodies such as gamma globulin
-Onset is within 24 hours of the dose and duration is about 4-6 months
97
Herd immunity
This occurs when a significant portion of the population is vaccinated and that provides a portion of immunity for those that have not developed immunity
-the population (herd) helps prevent disease in the unprotected population
-the herd protects those who cannot safely get vaccinations
-generally 90-95% of the population should be vaccinated to have effective herd immunity
98
Vaccine Contraindications:
I-P-A "beer"
IPV, PCV13, HepA = defer mod-severe illness
99
Vaccine Contraindications:
"A Painful Vaccine To Me"
HepA, PCV13, Varicella, Tdap, Meningococcal = minor site rxn
100
Vaccine Contraindications:
The Mental Defects Matter
Tdap, MMR, DTaP, Meningococcal = defer neuro; febrile seizures
101
Vaccine Contraindications:
Baby Is Happy
HepB, IPV, HiB = no reaction
102
Vaccine Contraindications:
"Vagina IZ A Hateful Monster"
Varicella, IPV, Zoster, HepA, HPV, MMR
103
Vaccine Contraindications:
allergic to yeast
HepB
104
Vaccine Contraindications:
Type 1 egg allergy
Influenza
105
Vaccine Contraindications:
GI issues/intussception
Rotavirus
106
Vaccine Contraindications:
Neomycin
MMR, IPV
107
Vaccine Contraindications:
Streptomycin/Polymyxin B
IPV
108
Vaccine Contraindications:
Gelatin/Latex
MMR
109
Vaccine Contraindications:
HIV
HepB, Influenza, PCV13, Tdap (w/Td given every 10 years - repeat) - protect against respiratory issues; don't give HVI patient live viruses
